MetLife Investment Management’s bluebird bio BLUE Stock Holding History

MetLife Investment Management’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5,608	Closed	-$110K	–	2855
2024 Q2	$110K	Buy	5,608 +586	+12%	+$11.7K	﹤0.01%	2560
2024 Q1	$129K	Buy	5,022 +2,296	+84%	+$58.9K	﹤0.01%	2420
2023 Q4	$75.2K	Hold	2,726	–	–	﹤0.01%	2717
2023 Q3	$166K	Hold	2,726	–	–	﹤0.01%	2312
2023 Q2	$179K	Hold	2,726	–	–	﹤0.01%	2344
2023 Q1	$173K	Buy	2,726 +545	+25%	+$62.2K	﹤0.01%	2301
2022 Q4	$302K	Buy	2,181 +280	+15%	+$39.4K	﹤0.01%	1990
2022 Q3	$241K	Hold	1,901	–	–	﹤0.01%	2163
2022 Q2	$157K	Buy	1,901 +1,147	+152%	+$89K	﹤0.01%	2466
2022 Q1	$73.2K	Sell	754 -471	-38%	-$62.2K	﹤0.01%	2651
2021 Q4	$245K	Sell	1,225 -666	-35%	-$157K	﹤0.01%	1934
2021 Q3	$468K	Hold	1,891	–	–	﹤0.01%	1556
2021 Q2	$783K	Buy	+1,891	New	+$749K	0.01%	1306
2019 Q2	–	Sell	-6	Closed	-$11.6K	–	2449
2019 Q1	$11.6K	Hold	6	–	–	﹤0.01%	2382
2018 Q4	$7.34K	Hold	6	–	–	﹤0.01%	2414
2018 Q3	$10.9K	Buy	+6	New	+$12.4K	﹤0.01%	2429
2018 Q1	–	Sell	-1,706	Closed	-$3.94M	–	2199
2017 Q4	$3.94M	Buy	+1,706	New	+$3.46M	0.04%	474

Other funds holding BLUE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MetLife Investment Management's BLUE Position: Q3 2024 in Review

MetLife Investment Management sold out of bluebird bio (BLUE) in Q3 2024, closing a stake of 5,608 shares — an estimated $110K sold.

MetLife Investment Management first reported a position in BLUE in Q4 2017 and held it in 17 quarters. The position peaked at $3.94M in Q4 2017. 140 funds tracked by Wall St. Rank hold BLUE as of Q3 2024.

MetLife Investment Management reported no remaining bluebird bio position as of Q3 2024 after selling out during the quarter.
MetLife Investment Management sold 5,608 bluebird bio shares in Q3 2024, an estimated $110K.
MetLife Investment Management first reported a position in bluebird bio in Q4 2017 and held it in 17 quarters.
MetLife Investment Management's bluebird bio position peaked at $3.94M in Q4 2017.
140 funds tracked by Wall St. Rank held bluebird bio as of Q3 2024.

Based on MetLife Investment Management's 13F filing for Q3 2024, filed 13 Nov 2024.